Clinical Trial

RBD5044 in Chinese Participants With Hypertriglyceridemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if drug RBD5044 works to treat hypertriglyceridemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are: Does drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat hypertriglyceridemia. Participants will: Receive RBD5044 or placebo twice during the trial (Day 1 and Day 84).
Trial Details
NCT Number NCT07587788
Lead Sponsor Ribotek Biopharmaceuticals (Shandong) Co., Ltd
Conditions Hypertriglyceridemia
Enrollment 40 participants
Start Date 2026-02-28
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-14